Evidence map›Paper›PMID 30845147›Full record

ArticlePloS one2019

In vitro efficacy of potentiated egg yolk powder against Campylobacter jejuni does not correlate with in vitro efficacy.

Amina Soumaila Garba, Alexandre Thibodeau, Audrey Perron, Sylvette Laurent-Lewandowski, Ann Letellier, Philippe Fravalo

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. IgYs: on her majesty's secret service.Frontiers in immunology · 2023
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amina Soumaila GarbaChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Alexandre ThibodeauChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.ORCID 0000-0003-1946-9143
Audrey PerronChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Sylvette Laurent-LewandowskiChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Ann LetellierChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Philippe FravaloChaire de Recherche industrielle du CRSNG en salubrité des viandes, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Natural Sciences and Engineering Research Council of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Campylobacter jejuni is a zoonotic agent responsible for the foodborne gastroenteritis campylobacteriosis. Control of C. jejuni load in the poultry primary production is recognized as an avenue to reduce human exposure to the pathogen. As for now, no commercially applicable control methods exist at the farm. Several studies tested egg yolk powders, potentiated or not against C. jejuni, as feed additives for chicken and suggested that the quantity and quality of the antibodies presence in the yolk are determinant factors for the full success of this approach. Unfortunately, data from these studies inconsistently showed a reduction of cecal C. jejuni carriage. Our first goal wwas to characterize (quantification by ELISA, agglutination test, bacterial antigen recognition profiles by Western blot, bactericidal effect by serum killing assays and C. jejuni mobility by soft agar migation) the antibodies extracted from egg yolk powders originating from different egg production protocols. Secondly, these powders were microencapsulated and recharacterized. Finally the protected powders were tested as a feed additive to destabilize C. jejuni colonization in an in vivo assay. Despite the in vitro results indicating the ability of the egg yolk powders to recognize Campylobacter and potentially alter its colonization of the chicken caecum, these results were not confirmed in the in vivo trial despite that specific caecal IgY directed toward Campylobacter were detected in the groups receiving the protected powders. More research is needed on Campylobacter in order to effectively control this pathogen at the farm.

Indexed as

Animal FeedAnimalsAntibodies, BacterialAntigens, BacterialBacterial LoadCampylobacter InfectionsCampylobacter jejuniCecumChickensDrug CompoundingDrug Evaluation, PreclinicalEgg YolkFood AdditivesFoodborne DiseasesImmunoglobulinsPoultry ProductsAntibodies, BacterialAntigens, BacterialFood AdditivesIgYImmunoglobulinsPowders

Identifiers

PMID30845147
PMCPMC6405129
OpenAlexW4231133287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.